Lead with the number, then the dependence. In its annual report for fiscal 2023, filed February 15, 2024, Vertex Pharmaceuticals reported full-year revenue of about $9.87 billion, up from roughly $8.93 billion in 2022 and about $7.57 billion in 2021. Three straight years of growth — and the cystic fibrosis franchise is still doing nearly all of the lifting.
That is the central tension of Vertex as its filings present it: a beautifully profitable, durable franchise that is also a concentration. Year after year, the CF business compounds, which is exactly what a great franchise should do — and exactly why the company keeps directing cash toward broadening beyond it.
The fundamentals-first read holds the two facts together. Roughly $9.9 billion in revenue is a powerful base, and steady growth off that base is a sign of a healthy core. But a single therapeutic area carrying the top line means the company’s long-run story still depends on whether a second engine arrives before the first one matures.
Read forward from early 2024, the question the 10-K leaves open is the same one it has posed for years: diversification. The filing records a company growing its CF franchise and investing beyond it; whether that investment becomes a second pillar is a future the document does not yet contain.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.